National Research (NRC) Competitors

National Research logo
$25.89 -0.44 (-1.67%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$25.93 +0.04 (+0.15%)
As of 08:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NRC vs. CERT, TDOC, GDRX, HSTM, and PHR

Should you buy National Research stock or one of its competitors? National Research's main competitors and comparable companies include Certara (CERT), Teladoc Health (TDOC), GoodRx (GDRX), HealthStream (HSTM), and Phreesia (PHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does National Research compare to Certara?

National Research (NASDAQ:NRC) and Certara (NASDAQ:CERT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

47.3% of National Research shares are owned by institutional investors. Comparatively, 74.0% of Certara shares are owned by institutional investors. 9.2% of National Research shares are owned by company insiders. Comparatively, 1.1% of Certara shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

National Research has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Certara has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

National Research has a net margin of 4.48% compared to Certara's net margin of -16.14%. National Research's return on equity of 313.25% beat Certara's return on equity.

Company Net Margins Return on Equity Return on Assets
National Research4.48% 313.25% 14.32%
Certara -16.14%3.36%2.31%

In the previous week, National Research and National Research both had 1 articles in the media. Certara's average media sentiment score of 1.43 beat National Research's score of 1.06 indicating that Certara is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
National Research
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Certara
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

National Research currently has a consensus target price of $27.00, suggesting a potential upside of 4.29%. Certara has a consensus target price of $9.92, suggesting a potential downside of 10.34%. Given National Research's higher probable upside, research analysts plainly believe National Research is more favorable than Certara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
National Research
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Certara
1 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.38

National Research has higher earnings, but lower revenue than Certara. Certara is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Research$137.39M4.00$11.60M$0.2892.46
Certara$418.84M4.03-$1.60M-$0.42N/A

Summary

National Research and Certara tied by winning 8 of the 16 factors compared between the two stocks.

How does National Research compare to Teladoc Health?

National Research (NASDAQ:NRC) and Teladoc Health (NYSE:TDOC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

National Research presently has a consensus price target of $27.00, suggesting a potential upside of 4.29%. Teladoc Health has a consensus price target of $8.53, suggesting a potential upside of 1.03%. Given National Research's stronger consensus rating and higher possible upside, analysts plainly believe National Research is more favorable than Teladoc Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
National Research
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Teladoc Health
2 Sell rating(s)
11 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.17

National Research has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Teladoc Health has a beta of 2, meaning that its share price is 100% more volatile than the broader market.

National Research has a net margin of 4.48% compared to Teladoc Health's net margin of -6.27%. National Research's return on equity of 313.25% beat Teladoc Health's return on equity.

Company Net Margins Return on Equity Return on Assets
National Research4.48% 313.25% 14.32%
Teladoc Health -6.27%-11.63%-5.53%

In the previous week, Teladoc Health had 5 more articles in the media than National Research. MarketBeat recorded 6 mentions for Teladoc Health and 1 mentions for National Research. National Research's average media sentiment score of 1.06 beat Teladoc Health's score of 0.98 indicating that National Research is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
National Research
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Teladoc Health
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

National Research has higher earnings, but lower revenue than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Research$137.39M4.00$11.60M$0.2892.46
Teladoc Health$2.53B0.61-$200.32M-$0.86N/A

47.3% of National Research shares are owned by institutional investors. Comparatively, 76.8% of Teladoc Health shares are owned by institutional investors. 9.2% of National Research shares are owned by insiders. Comparatively, 0.7% of Teladoc Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

National Research beats Teladoc Health on 11 of the 16 factors compared between the two stocks.

How does National Research compare to GoodRx?

National Research (NASDAQ:NRC) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

National Research has a net margin of 4.48% compared to GoodRx's net margin of 2.07%. National Research's return on equity of 313.25% beat GoodRx's return on equity.

Company Net Margins Return on Equity Return on Assets
National Research4.48% 313.25% 14.32%
GoodRx 2.07%7.22%2.53%

In the previous week, National Research and National Research both had 1 articles in the media. National Research's average media sentiment score of 1.06 beat GoodRx's score of 0.46 indicating that National Research is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
National Research
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GoodRx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

GoodRx has higher revenue and earnings than National Research. GoodRx is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Research$137.39M4.00$11.60M$0.2892.46
GoodRx$796.85M1.49$30.44M$0.0486.75

National Research has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, GoodRx has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

47.3% of National Research shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 9.2% of National Research shares are owned by company insiders. Comparatively, 5.9% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

National Research currently has a consensus target price of $27.00, suggesting a potential upside of 4.29%. GoodRx has a consensus target price of $4.15, suggesting a potential upside of 19.60%. Given GoodRx's higher probable upside, analysts clearly believe GoodRx is more favorable than National Research.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
National Research
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
GoodRx
3 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.08

Summary

National Research beats GoodRx on 9 of the 15 factors compared between the two stocks.

How does National Research compare to HealthStream?

HealthStream (NASDAQ:HSTM) and National Research (NASDAQ:NRC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

HealthStream has a net margin of 6.25% compared to National Research's net margin of 4.48%. National Research's return on equity of 313.25% beat HealthStream's return on equity.

Company Net Margins Return on Equity Return on Assets
HealthStream6.25% 6.37% 4.37%
National Research 4.48%313.25%14.32%

In the previous week, National Research had 1 more articles in the media than HealthStream. MarketBeat recorded 1 mentions for National Research and 0 mentions for HealthStream. HealthStream's average media sentiment score of 1.41 beat National Research's score of 1.06 indicating that HealthStream is being referred to more favorably in the media.

Company Overall Sentiment
HealthStream Positive
National Research Positive

HealthStream has higher revenue and earnings than National Research. HealthStream is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HealthStream$304.06M2.78$18.34M$0.7039.47
National Research$137.39M4.00$11.60M$0.2892.46

HealthStream pays an annual dividend of $0.14 per share and has a dividend yield of 0.5%. National Research pays an annual dividend of $0.64 per share and has a dividend yield of 2.5%. HealthStream pays out 20.0% of its earnings in the form of a dividend. National Research pays out 228.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. HealthStream has increased its dividend for 2 consecutive years.

HealthStream presently has a consensus price target of $36.00, suggesting a potential upside of 30.29%. National Research has a consensus price target of $27.00, suggesting a potential upside of 4.29%. Given HealthStream's higher probable upside, equities research analysts clearly believe HealthStream is more favorable than National Research.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HealthStream
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
National Research
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

HealthStream has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, National Research has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

69.6% of HealthStream shares are owned by institutional investors. Comparatively, 47.3% of National Research shares are owned by institutional investors. 20.4% of HealthStream shares are owned by company insiders. Comparatively, 9.2% of National Research shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

HealthStream beats National Research on 11 of the 19 factors compared between the two stocks.

How does National Research compare to Phreesia?

National Research (NASDAQ:NRC) and Phreesia (NYSE:PHR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

National Research has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, Phreesia has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

National Research has a net margin of 4.48% compared to Phreesia's net margin of 2.06%. National Research's return on equity of 313.25% beat Phreesia's return on equity.

Company Net Margins Return on Equity Return on Assets
National Research4.48% 313.25% 14.32%
Phreesia 2.06%5.22%3.02%

In the previous week, Phreesia had 4 more articles in the media than National Research. MarketBeat recorded 5 mentions for Phreesia and 1 mentions for National Research. National Research's average media sentiment score of 1.06 beat Phreesia's score of -0.27 indicating that National Research is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
National Research
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Phreesia
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

47.3% of National Research shares are held by institutional investors. Comparatively, 92.1% of Phreesia shares are held by institutional investors. 9.2% of National Research shares are held by company insiders. Comparatively, 5.2% of Phreesia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

National Research has higher earnings, but lower revenue than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Research$137.39M4.00$11.60M$0.2892.46
Phreesia$480.59M1.62$2.31M$0.1773.62

National Research presently has a consensus price target of $27.00, suggesting a potential upside of 4.29%. Phreesia has a consensus price target of $13.87, suggesting a potential upside of 10.79%. Given Phreesia's higher possible upside, analysts clearly believe Phreesia is more favorable than National Research.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
National Research
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Phreesia
2 Sell rating(s)
9 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.32

Summary

National Research beats Phreesia on 10 of the 16 factors compared between the two stocks.

Get National Research News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRC vs. The Competition

MetricNational ResearchHealthcare Technology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$558.76M$1.97B$7.83B$11.74B
Dividend Yield2.43%3.89%2.47%4.47%
P/E Ratio92.4739.6133.9728.44
Price / Sales4.005.568.495.70
Price / Cash20.9415.6721.0121.90
Price / Book-60.214.704.453.72
Net Income$11.60M-$19.09M$3.52B$393.10M
7 Day Performance-3.61%-7.92%-5.94%-5.77%
1 Month Performance28.49%-5.78%-4.58%-7.14%
1 Year Performance61.31%-11.43%-1.95%-7.47%

National Research Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRC
National Research
2.469 of 5 stars
$25.89
-1.7%
$27.00
+4.3%
+61.6%$558.76M$137.39M92.47357
CERT
Certara
1.8171 of 5 stars
$12.13
-0.7%
$9.92
-18.2%
+35.4%$1.86B$418.84MN/A1,576
TDOC
Teladoc Health
1.3961 of 5 stars
$8.93
-0.6%
$8.53
-4.4%
+24.7%$1.64B$2.53BN/A5,600
GDRX
GoodRx
3.4509 of 5 stars
$3.54
-3.0%
$4.15
+17.2%
+21.8%$1.25B$796.85M88.52697
HSTM
HealthStream
4.2865 of 5 stars
$28.71
-0.5%
$36.00
+25.4%
+13.1%$883.76M$304.06M41.011,160

Related Companies and Tools


This page (NASDAQ:NRC) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners